Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Acasti Pharma, Inc. (ACST)
NASDAQ:ACST
Holding ACST?
Track your performance easily
ACST Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.98 - $3.60
Previous Close$3.1
Volume27.80K
Average Volume (3M)30.70K
Market Cap
$32.85M
Enterprise Value$12.02M
Total Cash (Recent Filing)$19.41M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.51
Next Earnings
Nov 11, 2024EPS Estimate
-$0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.22
Shares Outstanding10,140,000
10 Day Avg. Volume48,692
30 Day Avg. Volume30,704
Standard Deviation0.29
R-Squared0.08
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)0.58
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.88
Forecast
1Y Price Target
$10.00Price Target Upside196.74% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Acasti Pharma News
PremiumCompany Announcements
Acasti Pharma’s Strategic Moves and Shareholder Decisions
PremiumCompany Announcements
Acasti Pharma Appoints Prashant Kohli as CEO with Incentives
Ownership Overview
12.94%
Insiders
― Other Institutional Investors
87.06% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ACST FAQ
What was Acasti Pharma, Inc.’s price range in the past 12 months?
Acasti Pharma, Inc. lowest stock price was $1.98 and its highest was $3.60 in the past 12 months.
What is Acasti Pharma, Inc.’s market cap?
Currently, no data Available
When is Acasti Pharma, Inc.’s upcoming earnings report date?
Acasti Pharma, Inc.’s upcoming earnings report date is Nov 11, 2024 which is 40 days ago.
How were Acasti Pharma, Inc.’s earnings last quarter?
Acasti Pharma, Inc. released its earnings results on Aug 09, 2024. The company reported -$0.24 earnings per share for the quarter, beating the consensus estimate of -$0.265 by $0.025.
Is Acasti Pharma, Inc. overvalued?
According to Wall Street analysts Acasti Pharma, Inc.’s price is currently Undervalued.
Does Acasti Pharma, Inc. pay dividends?
Acasti Pharma, Inc. does not currently pay dividends.
What is Acasti Pharma, Inc.’s EPS estimate?
Acasti Pharma, Inc.’s EPS estimate is -$0.4.
How many shares outstanding does Acasti Pharma, Inc. have?
Acasti Pharma, Inc. has 10,139,861 shares outstanding.
What happened to Acasti Pharma, Inc.’s price movement after its last earnings report?
Acasti Pharma, Inc. reported an EPS of -$0.24 in its last earnings report, beating expectations of -$0.265. Following the earnings report the stock price went down -3.279%.
Which hedge fund is a major shareholder of Acasti Pharma, Inc.?
Currently, no hedge funds are holding shares in ACST
---
Acasti Pharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.00 (196.74% Upside)
$10.00 (196.74% Upside)
Blogger Sentiment
Bullish
ACST Sentiment 100%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.1%
Last 30 Days ▲ 4.3%
Last 30 Days ▲ 4.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
35.00%
12-Months-Change
Fundamentals
Return on Equity
-18.56%
Trailing 12-Months
Asset Growth
-4.54%
Trailing 12-Months
Company Description
Acasti Pharma, Inc.
Acasti Pharma, Inc. engages in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. It focuses on the research of prescription drugs using omega-3, fatty acids derived from krill oil. The company was founded by Henri Harland on February 1, 2002 and is headquartered in Laval, Canada.
---
ACST Earnings Call
Q3 2023
0:00 / 0:00
---
ACST Stock 12 Month Forecast
Average Price Target
$10.00
▲(196.74% Upside)
Technical Analysis
Cyclacel Pharmaceuticals
―
ESSA Pharma
―
SELLAS Life Sciences Group
―
Avenue Therapeutics
―
Best Analysts Covering ACST
1 Year
1 Year Success Rate
5/5 ratings generated profit
1 Year Average Return
+13.10%
reiterated a buy rating 3 months ago
Copying Oren Livnat's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +13.10% per trade.
---